Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet C Lindsey

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour CommitteeDavid W Ellison, Olabisi E Onilude, Janet C Lindsey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
Rapid diagnosis of medulloblastoma molecular subgroupsEd C Schwalbe, Janet C Lindsey, Debbie Straughton, et al.
Neuro-Oncology|October 8, 2024
Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort studyEdward C Schwalbe, Janet C Lindsey, Marina Danilenko, et al.
The Lancet. Child & Adolescent Health|November 23, 2020
Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort studyRebecca M Hill, Stacey Richardson, Edward C Schwalbe, et al.
Neuropathology and Applied Neurobiology|April 7, 2021
Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnosticsStephen Crosier, Debbie Hicks, Edward C Schwalbe, et al.
Acta Neuropathologica|January 8, 2013
DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsiesEdward C Schwalbe, Daniel Williamson, Janet C Lindsey, et al.
Cell Reports|August 4, 2022
Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar developmentDaniel Williamson, Edward C Schwalbe, Debbie Hicks, et al.
The Lancet. Oncology|May 27, 2017
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort studyEdward C Schwalbe, Janet C Lindsey, Sirintra Nakjang, et al.
Neuro-Oncology|October 8, 2024
MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastomaMagretta Adiamah, Bethany Poole, Janet C Lindsey, et al.
Acta Neuropathologica|May 12, 2019
Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypesTanvi Sharma, Edward C Schwalbe, Daniel Williamson, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour CommitteeDavid W Ellison, Olabisi E Onilude, Janet C Lindsey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
Rapid diagnosis of medulloblastoma molecular subgroupsEd C Schwalbe, Janet C Lindsey, Debbie Straughton, et al.
Neuro-Oncology|October 8, 2024
Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort studyEdward C Schwalbe, Janet C Lindsey, Marina Danilenko, et al.
The Lancet. Child & Adolescent Health|November 23, 2020
Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort studyRebecca M Hill, Stacey Richardson, Edward C Schwalbe, et al.
Neuropathology and Applied Neurobiology|April 7, 2021
Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnosticsStephen Crosier, Debbie Hicks, Edward C Schwalbe, et al.
Acta Neuropathologica|January 8, 2013
DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsiesEdward C Schwalbe, Daniel Williamson, Janet C Lindsey, et al.
Cell Reports|August 4, 2022
Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar developmentDaniel Williamson, Edward C Schwalbe, Debbie Hicks, et al.
The Lancet. Oncology|May 27, 2017
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort studyEdward C Schwalbe, Janet C Lindsey, Sirintra Nakjang, et al.
Neuro-Oncology|October 8, 2024
MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastomaMagretta Adiamah, Bethany Poole, Janet C Lindsey, et al.
Acta Neuropathologica|May 12, 2019
Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypesTanvi Sharma, Edward C Schwalbe, Daniel Williamson, et al.
Pageof 3